MPI INDIUM DTPA IN 111 Drug Patent Profile
✉ Email this page to a colleague
When do Mpi Indium Dtpa In 111 patents expire, and what generic alternatives are available?
Mpi Indium Dtpa In 111 is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in MPI INDIUM DTPA IN 111 is indium in-111 pentetate disodium. There are twenty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indium in-111 pentetate disodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MPI INDIUM DTPA IN 111?
- What are the global sales for MPI INDIUM DTPA IN 111?
- What is Average Wholesale Price for MPI INDIUM DTPA IN 111?
Summary for MPI INDIUM DTPA IN 111
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 63 |
| DailyMed Link: | MPI INDIUM DTPA IN 111 at DailyMed |
Recent Clinical Trials for MPI INDIUM DTPA IN 111
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Vanderbilt-Ingram Cancer Center | Phase 1 |
| Instituto Nacional de Cancer, Brazil | Phase 1 |
| Gary Archer Ph.D. | Phase 2 |
US Patents and Regulatory Information for MPI INDIUM DTPA IN 111
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | MPI INDIUM DTPA IN 111 | indium in-111 pentetate disodium | INJECTABLE;INTRATHECAL | 017707-001 | Feb 18, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
